Global Gout Therapeutics Market - 2022-2029

Global Gout Therapeutics Market - 2022-2029

Market Overview

Gout Therapeutics Market size was valued US$ 1.9 billion in 2021 and is estimated to reach US$ 4.1 billion by 2029, growing at a CAGR of 8.2% during the forecast period (2022-2029).

Gout is a type of inflammatory arthritis caused by the overabundance of uric acid in the body, either producing too much or excreting too little. Gout can be acute and chronic. Acute gout mostly affects the major extremity joint, with the small joints of the hands and feet the most affected. In chronic gout, hard swellings (known as tophi) can form on the joints made of uric acid and grow large, even breaking through the skin. The global gout therapeutics market is impacted by several factors such as the rising prevalence of gout globally due to changes in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics.

Market Dynamics

The global gout therapeutics market growth is driven by the rising prevalence of gout globally due to changes in lifestyle, increasing alcohol consumption, increasing obesity & kidney diseases, high purine diet, and several medications diuretics are among the key factors driving the market growth.

Growing adoption of biologics and increasing R&D on regenerative medicines are expected to drive the global gout therapeutics market during the forecast period.

The major factors driving the growth of the market are the rising adoption of biologics and increasing R&D on regenerative medicines, technological advancements in imaging modalities improved. This condition can be treated or prevented with the use of drugs such as nonsteroidal anti-inflammatory drugs, corticosteroids, colchicine, and urate-lowering agents.

Biologics have witnessed rapid adoption and are replacing NSAIDs and corticosteroids owing to better results. Hence, the biologics segment is anticipated to expand at a rapid pace and is likely to gain gout therapeutics which drive the market growth in the forecast period.

Increasing product approvals by regulatory authorities are expected to drive the growth of the gout disease treatment market. Manufacturers are adopting acquisition & collaboration and new product development strategies to tap the unmet needs of a large proportion of the patient pool.

The new medication is being developed, such as arhalofenate, which is estimated to target renal transporters of uric acid, primarily URAT1 and OAT4, acting as uricosuric agents. Moreover, urate-lowering drugs are utilized for the symptomatic treatment of gout arthritis, as a first line of therapy or in combination therapy.

Side effects associated with gout therapeutics are likely to hinder the market growth

A prescription medicine used to treat gout is suspected to have caused 10 deaths in the U.S over the past eight years due to side effects that can sometimes be severe, according to the Food and Drug Administration (FDA). Colchicine, a strong anti-inflammatory that is widely used to treat gout, has been used for nearly 40 years and is one of the available options for the frontline treatment of people with gout. A total of 17 colchicine products have been licensed by the FDA and about 38 million colchicine tablets are sold in the nation each year, the FDA said. However, from 2011 to August this year, the FDA received 353 reports suggesting adverse reactions to the drug, mostly among patients with renal and liver dysfunction, with 10 deaths believed to be linked to the problem. People with renal or hepatic impairment and those who also take other drugs for chronic diseases could experience serious side effects from colchicine.

In addition, corticosteroids, such as prednisone, can be prescribed to reduce pain and inflammation. They can increase blood sugar levels and blood pressure and may induce mood changes. Side effects can include nausea, diarrhea and vomiting. In Japan, Europe and the US, there have been reports of patients dying of renal failure after using benzbromarone, because of the side effects, doctors tend to prescribe low-dose colchicine for people with renal or hepatic impairment. Thus, factors such as the adverse effects of the drugs may restrain the market growth.

Industry Analysis

The global gout therapeutics market provides in-depth analysis of the market based on various industry factors such as porter’s five forces, regulatory analysis, supply chain analysis, pricing analysis, pipeline, unmet needs, epidemiology.

^COVID-19.+ Impact Analysis

The Covid – 19 pandemic is expected to impact the growth of the gout therapeutics market over the forecast period. According to CreakyJoints, in May 2020, people with gout may be considered in a higher-risk group for potential COVID-19 complications. The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic.

With the ongoing COVID-19 pandemic, several companies are testing their drugs for their treatment. For instance, on June 22nd, 2020, the anti-viral drug Favipiravir (Fabiflu) was approved for the treatment of mild to moderate COVID-19 patients and will be commercialized full scale in a week, says drugmaker Glenmark Pharmaceuticals. The Drug Controller General of India approved the anti-viral for 'restricted emergency use' for treatment of mild to moderate cases, which accounts for a majority of COVID-19 infections.

Colchicine, an anti-inflammatory drug used to treat gout and rheumatic disease, may be a promising treatment for COVID-19, a randomized, open-label trial suggests. In the Greek Study on the Effects of Colchicine in COVID-19 Complications Prevention (GRECCO-19), investigators randomly assigned 105 patients who had COVID-19 to receive either the standard of care or the standard of care plus colchicine for 3 weeks. They found that for patients in the colchicine group, the time to clinical deterioration improved, although there were no significant differences between the groups in cardiac and inflammatory biomarkers.

Segment Analysis/B>

The non-steroidal anti-inflammatory drugs (NSAIDs) segment is expected to hold the largest market share in global gout therapeutics market

The non-steroidal anti-inflammatory drugs (NSAIDs) are estimated to dominate the market, owing to the availability of these drugs at a lower cost compared to other drugs, high level of penetration of drugs, and the ability to relieve pain in case of an acute gout attack.

NSAIDs are the first-line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases. The rising number of gout patients, low cost of drugs, and application in combination therapy is likely to drive the market Indomethacin and naproxen are the major choice for the acute attack of gout.

NSAIDs decrease pain and swelling. Some NSAIDs are available over-the-counter, like ibuprofen and naproxen sodium. Stronger NSAIDs like indomethacin and celecoxib are prescribed by the doctor. Although NSAID effects on pain tend to be patient-specific, naproxen and indomethacin are common choices. Use of concomitant gastric protection with misoprostol or consideration of a cyclooxygenase-2 (COX-2)–specific NSAID might be considered if the patient has gastrointestinal (GI) risk or is older than 51 years.

To control the attack as quickly and safely as possible (recalling that it takes 5 half-lives to reach a steady state), NSAIDs with a short half-life (eg, ketoprofen, ibuprofen, or diclofenac) are preferred.

Geographical Analysis

North America region holds the largest market share in the global gout therapeutics market

North America is dominating the global gout therapeutics market, accounting for the largest market share, owing to the large presence of major players, high demand for gout therapy, and high cost of branded pharmaceuticals U.S. Also, the research and development of new drugs for gout treatment is expected to show dominance over the forecast period. In June 2020, Pharma major Dr. Reddy's Laboratories launched the generic Colchicine caused to prevent and treat acute gout flares in the US market.

The Asia Pacific region is expected to grow at the fastest growth rate over the forecast period owing to the diversified patient pool, and growing investment by major players with local manufacturers, and hospital chains in growing countries such as India, China, South Korea, and other South Asian countries. According to the Australian Institute of Health and Welfare report 2022, in 2017-2018, gout cost the Australian health system an estimated USD 196.5 million, representing 1.4% of disease expenditure on musculoskeletal conditions and 0.2% of total disease expenditure. Besides, changing lifestyles with a rising prevalence of smoking & alcohol consumption is expected to boost gout incidence over the period.

In December 2022, Selecta Biosciences, Inc., a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, completed the patient enrollment in the six-month, head-to-head, Phase 2 COMPARE clinical trial. The trial evaluates the superiority of a once-monthly dose of Selecta’s lead product candidate, SEL-212 (ImmTOR + pegadricase), versus a bi-weekly dose of pegloticase, the current FDA-approved uricase therapy for adult patients with chronic refractory gout.

Demand for effective therapeutics for gout treatment is increasing. Numerous pipeline products and recent approvals of drugs to treat gout arthritis are expected to drive the market in the region. According to estimates more than 2 million people in the U.S. take medication to decrease serum uric acid levels. However, factors such as increasing competition in the generic sector, patent expiry of blockbuster products, and the high cost of the newly launched drugs are likely to hinder the growth of the market in the United States.

The Public Health Agency of Canada (PHAC), in collaboration with all Canadian provinces and territories, conducts national surveillance of gout and supports public health action.

Competitive Landscape

The global market for gout therapeutics is fragmented and highly competitive and consists of several major players. Few major players dominate the market share, and few emerging companies are expected to enter the market over the forecast period. Some of the market's major players market is Horizon Therapeutics plc, Lannett Company, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Ltd, and Mylan. The key players are adopting various growth strategies such as product launches, acquisitions, and collaborations, contributing to the global market's growth globally. For instance, On March 2nd, 2020, Avion Pharmaceuticals launched Gloperba (colchicine) oral solution for prophylaxis of gout flares in adults.

Companies are entering into collaborations, acquisitions, mergers, approvals and licensing for increasing their market penetration. In January 2020, US-based Novadoz Pharmaceuticals received FDA approval for their generic version of Febuxostat 40mg and 80mg tablets. The approved product is AB-rated to the brand Uloric, marketed by Takeda Pharmaceuticals America, Inc.

Key Companies to Watch

Novartis AG:

Overview: Novartis AG develops, manufactures, and markets healthcare products. The company mainly operates through three business segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics.

Product Portfolio:

Canakinumab: Canakinumab is a fully human monoclonal antibody targeting IL 1b that has an expanding list of clinical indications. Novartis’ canakinumab, an IL-1B inhibitor, has shown remarkable clinical success in treating gout.

Key Developments: In Jun 2022, Novartis announced the approval of Cosentyx by the European Commission (EC). It is used for treatment of juvenile idiopathic arthritis (JIA) a category of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) in patients ages 6 years or older.

The global gout therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.